Nuevolution has announced that it has entered into a non-exclusive technology licensing agreement with Novartis for use of Nuevolution’s Chemetics technology.
The Chemetics platform uses proprietary innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming drug-like small molecules for lead discovery. The technology allows efficient screening of billions of molecules against biological targets. Nuevolution has patented its Chemetics technology and holds a strong validated patent portfolio within the technology field. In its existing collaborations and internal pipeline development, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.
Nuevolution will transfer know-how to Novartis to enable Novartis to practice the technology for its internal use, and the companies will work together to co-produce novel screening libraries.
Under the terms of the agreement, Novartis will provide Nuevolution with an upfront payment, research funding, and milestone payments as technology transfer progresses. Further financial details are not disclosed.
“It’s a main strategy for us to boost the application of our Chemetics technology both by having internal programs as well as by application of the technology in partnerships and licensing arrangements. By entering into this agreement with Novartis, multiple Novartis research projects will benefit from having efficient access to much broader chemistry space in the search for the best drug candidates addressing major unmet medical needs,“ said Alex Gouliaev, CEO of Nuevolution A/S and continued, “We are looking forward to continue the excellent working relationship with Novartis’ dedicated team to successfully transfer our technology for the practice by Novartis.”
This is the second agreement between Nuevolution and Novartis. In 2009, the companies entered into a drug discovery collaboration in which Nuevolution applied its proprietary Chemetics drug discovery technology against a limited number of drug targets of interest to Novartis.